title: Topical dexamethasone-cyclodextrin nanoparticle eye drops for non-infectious Uveitic macular oedema and vitritis - a pilot study.
abstract: OBJECTIVE
  To evaluate the safety and efficacy of 1.5% dexamethasone nanoparticle (DexNP) drops in eyes with non-infectious uveitic macular oedema and vitritis.
  
  
  METHODS
  In a prospective pilot study, DexNP drops were administered four times a day for 4 weeks followed by drops tapering over a period of another 4 weeks. Follow-up time was 12 weeks.
  
  
  RESULTS
  Five eyes with macular oedema and three eyes with vitritis were included in the study. Best corrected visual acuity (BCVA) significantly improved from a median of 0.2 logMAR to a median of 0.15 logMAR at 4 weeks' time (p < 0.05). Median BCVA was 0.175 logMAR and 0.2 logMAR, at week 8 and 12, respectively (p > 0.05). Macular oedema significantly improved at all time-points as compared to baseline (p < 0.05) and resolved in all eyes during follow-up. One eye had macular oedema relapse at week 12. Vitritis improved in all eyes and resolved completely in two eyes. One eye had intraocular pressure (IOP) elevation which was well controlled with topical antihypertensive treatment, and one eye had cataract progression.
  
  
  CONCLUSIONS
  This short pilot study demonstrates favourable effect of 1.5% DexNP eye drops on eyes with non-infectious uveitic macular oedema and vitritis. Further comparative long-term studies are warranted to assess this effect.
authors.affiliation: Division of Ophthalmology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Shiri
authors.initials: S
authors.lastname: Shulman
authors.affiliation: Department of Clinical Science, Ophthalmology, Umeå University, Umeå, Sweden.
authors.forename: Gauti
authors.initials: G
authors.lastname: Jóhannesson
authors.affiliation: Department of Ophthalmology, National Hospital Reykjavik, University of Iceland, Reykjavik, Iceland.
authors.forename: Einar
authors.initials: E
authors.lastname: Stefánsson
authors.affiliation: Division of Ophthalmology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Anat
authors.initials: A
authors.lastname: Loewenstein
authors.affiliation: Division of Ophthalmology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Amir
authors.initials: A
authors.lastname: Rosenblatt
authors.affiliation: Division of Ophthalmology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Zohar
authors.initials: Z
authors.lastname: Habot-Wilner
mesh_terms: D000287:Administration, Topical; D000368:Aged; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry; D005128:Eye Diseases / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D053758:Nanoparticles / Q000737:chemistry; D009883:Ophthalmic Solutions; D010865:Pilot Projects; D011446:Prospective Studies; D012160:Retina / Q000473:pathology; D014605:Uveitis / Q000188:drug therapy*; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body / Q000187:drug effects*; D047392:beta-Cyclodextrins / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry
chemical_list: D005938:Glucocorticoids; D009883:Ophthalmic Solutions; D047392:beta-Cyclodextrins; C100693:dexamethasone-beta-cyclodextrin; D003907:Dexamethasone
keywords: 1.5% dexamethasone nanoparticle eye drops; dexamethasone-cyclodextrin nanoparticle eye drops; intermediate uveitis; non-infectious uveitis; uveitic macular oedema; vitritis